Trials / Recruiting
RecruitingNCT01898663
DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML
Safety and Therapeutic Efficacy of DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML: a Phase Ⅰ/Ⅱ Study
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this Phase Ⅰ/Ⅱ study is to evaluate the safety and efficacy of dendritic cells (DCs) vaccine combined with cytokine-induced killer (CIK) cells in patients with AML. Experimental recombinant adenovirus-transfected DCs, which engineered to express MUC1 and Survivin are used for DCs-based immunotherapy. Based on the results of our previously performed preclinical study with DCs vaccine combined with CIK cells, the investigators plan to perform the clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Adenovirus-transfected DC + CIK | Adenovirus-transfected autologous DC vaccine plus CIK cells |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
- First posted
- 2013-07-12
- Last updated
- 2024-07-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01898663. Inclusion in this directory is not an endorsement.